Biomarkers are molecular indicators of a biological status and, as biochemical species, can be interrogated to evaluate disease status and therapeutic interventions. Biomarkers may be detectable in the blood, other body fluids, or tissues. The expectation is that the level of an informative biomarker is related to the specific type of disease present in the body. Hence, disease-relevant biomarkers can be used to measure the presence, progress, or intensity of disease. Through a variety of mechanisms, cancer cells provide the biomarker material for their own detection. Tumor biomarkers include cancer-specific mutations or changes in gene expression, both of which can result in aberrant protein expression. These variant or abundant proteins can be detectable in the circulation as the free proteins or as novel autoantibodies to those proteins, the latter indicating that the immune system can provide an exquisitely sensitive sensor of disease. Because cancer cells shed DNA in the circu- tion, an event rarely seen in healthy individuals, tumor-specific genetic changes, such as promoter methylation or gene mutations, are detectable in DNA prepared from plasma or other body fluids. Cancer-related biochemical changes often effect measurable me- bolic variations within a cell or organism. In addition, these biochemical changes result in posttranslational modification of proteins via glycosylation or phosphorylation providing a plethora of opportunity for biomarker discovery.
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
Through a variety of mechanisms, cancer cells provide the biomarker material that can lead to their own detection, which then grants clinicians the opportunity for non-invasive body fluid and tissue analysis able to indicate the presence of tumors or the level of tumor burden. In Tumor Biomarker Discovery: Methods and Protocols, experts in the field present detailed chapters focused on the use and development of panels of biomarker analytes while covering subjects such as nucleic acids and protein-based technologies, metabolic profiling by analytic means or spectroscopy, as well as study designs for biomarker discovery and validation. Written in the highly successful Methods in Molecular Biology™ series format, chapters include brief introductions to the topics, lists of the necessary materials or reagents, step-by-step laboratory protocols, and notes on troubleshooting and avoiding known pitfalls.
Cutting-edge and authoritative, Tumor Biomarker Discovery: Methods and Protocols is an ideal guide to the technologies that can be used to discover and validate tumor biomarker panels suitable for the presymptomatic early detection of cancer.
„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.
EUR 64,39 für den Versand von USA nach Deutschland
Versandziele, Kosten & DauerEUR 2,30 für den Versand innerhalb von/der Deutschland
Versandziele, Kosten & DauerAnbieter: Biblios, Frankfurt am main, HESSE, Deutschland
Zustand: New. pp. 332. Bestandsnummer des Verkäufers 18523976
Anzahl: 1 verfügbar
Anbieter: Books Puddle, New York, NY, USA
Zustand: New. pp. 332 1st Edition. Bestandsnummer des Verkäufers 26523970
Anzahl: 1 verfügbar
Anbieter: Majestic Books, Hounslow, Vereinigtes Königreich
Zustand: New. pp. 332. Bestandsnummer des Verkäufers 7356701
Anzahl: 1 verfügbar
Anbieter: Research Ink, Takoma Park, MD, USA
Hardback. Zustand: Very Good. xi + 332 pp. Methods in Molecular Biology, volume 520. Rubber-stamped on one of the front pages. book. Bestandsnummer des Verkäufers 25264
Anzahl: 1 verfügbar
Anbieter: Basi6 International, Irving, TX, USA
Zustand: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service. Bestandsnummer des Verkäufers ABEJUNE24-374038
Anzahl: 1 verfügbar
Anbieter: ALLBOOKS1, Direk, SA, Australien
Bestandsnummer des Verkäufers SHUB374038
Anzahl: 1 verfügbar
Anbieter: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Deutschland
Buch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Biomarkers are molecular indicators of a biological status and, as biochemical species, can be interrogated to evaluate disease status and therapeutic interventions. Biomarkers may be detectable in the blood, other body fluids, or tissues. The expectation is that the level of an informative biomarker is related to the specific type of disease present in the body. Hence, disease-relevant biomarkers can be used to measure the presence, progress, or intensity of disease. Through a variety of mechanisms, cancer cells provide the biomarker material for their own detection. Tumor biomarkers include cancer-specific mutations or changes in gene expression, both of which can result in aberrant protein expression. These variant or abundant proteins can be detectable in the circulation as the free proteins or as novel autoantibodies to those proteins, the latter indicating that the immune system can provide an exquisitely sensitive sensor of disease. Because cancer cells shed DNA in the circu- tion, an event rarely seen in healthy individuals, tumor-specific genetic changes, such as promoter methylation or gene mutations, are detectable in DNA prepared from plasma or other body fluids. Cancer-related biochemical changes often effect measurable me- bolic variations within a cell or organism. In addition, these biochemical changes result in posttranslational modification of proteins via glycosylation or phosphorylation providing a plethora of opportunity for biomarker discovery. 332 pp. Englisch. Bestandsnummer des Verkäufers 9781603278102
Anzahl: 2 verfügbar
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Buch. Zustand: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Biomarkers are molecular indicators of a biological status and, as biochemical species, can be interrogated to evaluate disease status and therapeutic interventions. Biomarkers may be detectable in the blood, other body fluids, or tissues. The expectation is that the level of an informative biomarker is related to the specific type of disease present in the body. Hence, disease-relevant biomarkers can be used to measure the presence, progress, or intensity of disease. Through a variety of mechanisms, cancer cells provide the biomarker material for their own detection. Tumor biomarkers include cancer-specific mutations or changes in gene expression, both of which can result in aberrant protein expression. These variant or abundant proteins can be detectable in the circulation as the free proteins or as novel autoantibodies to those proteins, the latter indicating that the immune system can provide an exquisitely sensitive sensor of disease. Because cancer cells shed DNA in the circu- tion, an event rarely seen in healthy individuals, tumor-specific genetic changes, such as promoter methylation or gene mutations, are detectable in DNA prepared from plasma or other body fluids. Cancer-related biochemical changes often effect measurable me- bolic variations within a cell or organism. In addition, these biochemical changes result in posttranslational modification of proteins via glycosylation or phosphorylation providing a plethora of opportunity for biomarker discovery. Bestandsnummer des Verkäufers 9781603278102
Anzahl: 2 verfügbar
Anbieter: moluna, Greven, Deutschland
Zustand: New. Provides a detailed overview of the range of biomarker technologies as written by leading researchers in the fieldUseful both for researchers interested in new tumor biomarkers and physicians seeking familiarity with new technologies in the clinic. Bestandsnummer des Verkäufers 102938151
Anzahl: 3 verfügbar
Anbieter: Anybook.com, Lincoln, Vereinigtes Königreich
Zustand: Good. Volume 520. This is an ex-library book and may have the usual library/used-book markings inside.This book has hardback covers. In good all round condition. No dust jacket. Please note the Image in this listing is a stock photo and may not match the covers of the actual item,950grams, ISBN:9781603278102. Bestandsnummer des Verkäufers 4315655
Anzahl: 1 verfügbar